US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Everus Construction Group, Inc.

88.09

-13.1200-12.96%

Post-market: 88.090.00000.00%17:56 EST

Volume:1.71M

Turnover:153.37M

Market Cap:4.49B

PE:24.89

High:101.12

Open:101.12

Low:84.58

Close:101.21

52wk High:103.08

52wk Low:31.38

Shares:51.01M

Float Shares:50.85M

Volume Ratio:3.36

T/O Rate:3.37%

Dividend:- -

Dividend Rate:- -

EPS(TTM):3.54

EPS(LYR):2.81

ROE:35.26%

ROA:10.41%

PB:7.84

PE(LYR):31.31

Loading ...

Overview Company News Filings

Stock Track | Everus Construction Group Soars 13.14% on Impressive Q3 Results: Revenue Up 30%, EBITDA Rises 37%

Stock Track | Everus Construction Group Soars 10.82% Pre-market on Strong Q3 Results: 30% Revenue Growth, 37% EBITDA Increase

Stock Track | Everus Construction Group Soars 10.82% Pre-market on Strong Q3 Results: Revenue Up 30%, EBITDA Rises 37%

Wearable Devices and X-trodes Successfully Deliver Neural Interface System for Dynamic, Real-World Environments

Everus Construction Group Inc. reports 30% revenue growth and 37% EBITDA increase in Q3 2025

GUIDANCE: (ECG) Everus Expects Full Year 2025 Revenue Range $3.55B - $3.65B, vs. FactSet Est of $3.38B

MT Newswires Live

Earnings Flash (ECG) Everus Posts Q3 EPS $1.11, vs. FactSet Est of $0.62

MT Newswires Live

Everus Construction Group Q3 EPS $1.11 Beats $0.65 Estimate, Sales $986.800M Beat $830.600M Estimate

Everus Construction Group Inc. reports third quarter revenue of $986.8 million and net income of $57.0 million

Everus Construction Group - Qtrly REV $986.8 Mln, Diluted EPS $1.11

THOMSON REUTERS

Everus Construction Group Inc: FY Revenues Expected to Be in Range of $3.55 Bln to $3.65 Bln

THOMSON REUTERS

Press Release: Everus Reports Third Quarter Results, Raises Guidance for 2025

CardioComm Secures $512,000 Loan to Advance ECG Software Platform

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

A Look at Everus Construction Group’s Valuation After Strong Q2 2025 Earnings Beat and Upgraded Outlook

Simply Wall St.

New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $133B Cardiac Diagnostics Market

HeartBeam (NASDAQ: BEAT) Partners with HeartNexus to Deliver 24/7 Remote Cardiology Services and Real-Time ECG Interpretation

zSpace Expands Health Science Portfolio with New Immersive Applications for Anatomy and ECG Training

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ECG/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ECG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ECG\",,,,,undefined,":{"symbol":"ECG","market":"US","secType":"STK","nameCN":"Everus Construction Group, Inc.","latestPrice":88.09,"timestamp":1765573200000,"preClose":101.21,"halted":0,"volume":1713938,"hourTrading":{"tag":"盘后","latestPrice":88.09,"preClose":88.09,"latestTime":"17:56 EST","volume":38837,"amount":3421170.99,"timestamp":1765580176166},"delay":0,"floatShares":50847531,"shares":51006575,"eps":3.53914,"marketStatus":"Market Closed","change":-13.12,"latestTime":"12-12 16:00:00 EST","open":101.12,"high":101.12,"low":84.58,"amount":153371450.56054,"amplitude":0.163423,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":3.53914,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":101.21,"preHourTrading":{"tag":"盘前","latestPrice":101,"preClose":101.21,"latestTime":"08:00 EST","volume":3228,"amount":327109.60596,"timestamp":1765544400256},"postHourTrading":{"tag":"盘后","latestPrice":88.09,"preClose":88.09,"latestTime":"17:56 EST","volume":38837,"amount":3421170.99,"timestamp":1765580176166},"volumeRatio":3.362413837612781,"impliedVol":0.5259,"impliedVolPercentile":0.4144},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ECG\",,,,,undefined,":{"symbol":"ECG","floatShares":50847531,"roa":"10.41%","roe":"35.26%","lyrEps":2.813666,"volumeRatio":3.362413837612781,"shares":51006575,"dividePrice":0,"high":101.12,"amplitude":0.163423,"preClose":101.21,"low":84.58,"week52Low":31.38,"pbRate":"7.84","psRate":"1.29","week52High":103.08,"institutionHeld":0,"latestPrice":88.09,"eps":3.53914,"divideRate":0,"volume":1713938,"delay":0,"ttmEps":3.53914,"open":101.12,"prevYearClose":65.75,"prevWeekClose":91.75,"prevMonthClose":91.96,"prevQuarterClose":85.75,"fiveDayClose":91.75,"twentyDayClose":91.58,"sixtyDayClose":81.89},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ECG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-04","symbol":"ECG","fiscalQuarterEnding":"2025/09","expectedEps":0.62,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":1.11},{"market":"US","date":"2025-08-12","symbol":"ECG","fiscalQuarterEnding":"2025/06","expectedEps":0.61,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"post","actualEps":1.03},{"market":"US","date":"2025-05-13","symbol":"ECG","fiscalQuarterEnding":"2025/03","expectedEps":0.43,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"post","actualEps":0.72},{"market":"US","date":"2025-02-11","symbol":"ECG","fiscalQuarterEnding":"2024/12","expectedEps":0.73,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1739250000000,"reportTimeType":"post","actualEps":0.67}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ECG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ECG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":4,"updateTime":1733374800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ECG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ECG","date":"2025-12-11","current":24.890228,"percent":0.892989,"low":11.94786,"twenty":16.658219,"median":23.613932,"eighty":25.8411,"high":28.892955,"avg":22.277119,"sd":4.647106,"marketCap":4909382843},"quantilePoints":[{"date":"2024-11-15","current":19.884731,"twenty":20.580031,"median":21.388177,"eighty":22.118522,"marketCap":2892154627},{"date":"2024-11-22","current":22.527151,"twenty":20.580031,"median":21.221711,"eighty":22.118522,"marketCap":3276483952},{"date":"2024-11-29","current":22.309869,"twenty":20.774883,"median":21.784189,"eighty":22.44935,"marketCap":3244881275},{"date":"2024-12-06","current":23.914946,"twenty":20.948708,"median":22.309869,"eighty":22.694667,"marketCap":3478333306},{"date":"2024-12-13","current":24.1112,"twenty":21.255005,"median":22.386969,"eighty":23.504916,"marketCap":3506877659},{"date":"2024-12-20","current":22.639296,"twenty":21.463875,"median":22.621773,"eighty":23.900227,"marketCap":3292795011},{"date":"2024-12-27","current":25.796882,"twenty":21.726014,"median":22.804009,"eighty":24.031297,"marketCap":3752053262},{"date":"2025-01-03","current":24.279418,"twenty":22.045628,"median":23.042317,"eighty":24.098584,"marketCap":3531344247},{"date":"2025-01-10","current":23.36123,"twenty":22.054038,"median":23.36123,"eighty":24.167273,"marketCap":3397797452},{"date":"2025-01-17","current":23.231562,"twenty":22.309869,"median":23.296396,"eighty":24.223346,"marketCap":3378937791},{"date":"2025-01-24","current":26.403166,"twenty":22.309869,"median":23.448843,"eighty":24.416796,"marketCap":3840234925},{"date":"2025-01-31","current":24.703467,"twenty":22.363139,"median":23.511925,"eighty":24.431515,"marketCap":3593020438},{"date":"2025-02-07","current":24.784071,"twenty":22.393278,"median":23.631079,"eighty":24.431515,"marketCap":3604744012},{"date":"2025-02-14","current":17.609659,"twenty":22.363139,"median":23.694161,"eighty":24.484083,"marketCap":2525594974},{"date":"2025-02-21","current":16.543269,"twenty":22.049833,"median":23.511925,"eighty":24.443431,"marketCap":2372652202},{"date":"2025-02-28","current":14.893919,"twenty":20.948708,"median":23.398027,"eighty":24.417497,"marketCap":2136100715},{"date":"2025-03-07","current":14.060071,"twenty":19.828659,"median":23.326185,"eighty":24.358924,"marketCap":2016509475},{"date":"2025-03-14","current":13.437787,"twenty":16.836882,"median":23.135188,"eighty":24.308591,"marketCap":1927260826},{"date":"2025-03-21","current":14.294761,"twenty":15.304834,"median":22.94419,"eighty":24.287829,"marketCap":2050168965},{"date":"2025-03-28","current":12.43502,"twenty":14.540119,"median":22.651562,"eighty":24.245775,"marketCap":1783443003},{"date":"2025-04-04","current":12.555921,"twenty":14.128344,"median":22.527151,"eighty":24.214935,"marketCap":1800782740},{"date":"2025-04-11","current":13.501793,"twenty":13.910012,"median":22.343162,"eighty":24.184095,"marketCap":1936440687},{"date":"2025-04-17","current":13.572911,"twenty":13.722422,"median":22.181953,"eighty":24.146246,"marketCap":1946640532},{"date":"2025-04-25","current":14.568566,"twenty":13.695946,"median":21.51434,"eighty":24.113303,"marketCap":2089438371},{"date":"2025-05-02","current":15.233522,"twenty":13.71017,"median":20.922073,"eighty":24.085968,"marketCap":2184806927},{"date":"2025-05-09","current":17.164381,"twenty":13.722422,"median":19.902399,"eighty":24.031297,"marketCap":2461732735},{"date":"2025-05-16","current":20.563833,"twenty":13.745616,"median":19.893565,"eighty":23.999055,"marketCap":3123214340},{"date":"2025-05-23","current":21.992869,"twenty":13.78911,"median":20.563833,"eighty":23.959104,"marketCap":2926865953},{"date":"2025-05-30","current":22.176813,"twenty":13.823958,"median":20.788901,"eighty":23.91004,"marketCap":2951345752},{"date":"2025-06-06","current":23.146354,"twenty":13.877297,"median":21.451259,"eighty":23.877799,"marketCap":3080374692},{"date":"2025-06-13","current":23.161683,"twenty":13.948415,"median":21.770602,"eighty":23.816119,"marketCap":3082414675},{"date":"2025-06-20","current":22.912591,"twenty":13.971173,"median":22.043525,"eighty":23.771261,"marketCap":3049264947},{"date":"2025-06-27","current":23.740342,"twenty":14.060071,"median":22.121246,"eighty":23.740342,"marketCap":3159424042},{"date":"2025-07-03","current":24.970471,"twenty":14.07145,"median":22.251005,"eighty":23.895321,"marketCap":3323132697},{"date":"2025-07-11","current":25.805886,"twenty":14.153947,"median":22.376456,"eighty":24.052477,"marketCap":3434311784},{"date":"2025-07-18","current":26.518671,"twenty":14.202307,"median":22.526346,"eighty":24.175684,"marketCap":3529171005},{"date":"2025-07-25","current":26.442027,"twenty":14.212264,"median":22.621773,"eighty":24.30109,"marketCap":3518971089},{"date":"2025-08-01","current":28.457753,"twenty":14.278404,"median":22.671329,"eighty":24.416796,"marketCap":3787228885},{"date":"2025-08-08","current":27.411568,"twenty":14.30614,"median":22.782297,"eighty":24.537352,"marketCap":3648000028},{"date":"2025-08-15","current":23.175295,"twenty":14.422774,"median":22.810398,"eighty":24.635911,"marketCap":3841305163},{"date":"2025-08-22","current":23.323006,"twenty":14.493892,"median":22.904927,"eighty":24.537352,"marketCap":3865788319},{"date":"2025-08-29","current":24.713955,"twenty":14.521629,"median":22.920255,"eighty":24.537352,"marketCap":4096338038},{"date":"2025-09-05","current":23.815378,"twenty":14.551498,"median":22.978193,"eighty":24.507914,"marketCap":3947398839},{"date":"2025-09-12","current":24.372372,"twenty":14.649641,"median":23.042317,"eighty":24.488989,"marketCap":4039720740},{"date":"2025-09-19","current":25.200171,"twenty":14.753844,"median":23.089828,"eighty":24.488989,"marketCap":4176928426},{"date":"2025-09-26","current":24.396991,"twenty":14.851263,"median":23.146354,"eighty":24.588002,"marketCap":4043801266},{"date":"2025-10-03","current":25.117084,"twenty":14.97923,"median":23.180649,"eighty":24.722376,"marketCap":4163156651},{"date":"2025-10-10","current":27.003481,"twenty":15.154555,"median":23.193759,"eighty":24.845751,"marketCap":4475826956},{"date":"2025-10-17","current":27.852821,"twenty":15.383802,"median":23.275964,"eighty":25.02914,"marketCap":4616605103},{"date":"2025-10-24","current":26.926548,"twenty":15.791108,"median":23.323006,"eighty":25.217404,"marketCap":4463075312},{"date":"2025-10-31","current":27.600481,"twenty":16.024903,"median":23.341955,"eighty":25.414653,"marketCap":4574779711},{"date":"2025-11-07","current":27.713121,"twenty":16.093341,"median":23.36123,"eighty":25.523906,"marketCap":5014966454},{"date":"2025-11-14","current":25.813341,"twenty":16.136723,"median":23.428153,"eighty":25.800484,"marketCap":4671182138},{"date":"2025-11-21","current":22.66771,"twenty":16.383495,"median":23.439945,"eighty":25.708429,"marketCap":4101948761},{"date":"2025-11-28","current":25.92045,"twenty":16.548957,"median":23.449096,"eighty":25.737913,"marketCap":4690564637},{"date":"2025-12-05","current":26.630754,"twenty":16.561288,"median":23.487393,"eighty":25.810359,"marketCap":4819101206},{"date":"2025-12-11","current":27.129658,"twenty":16.658219,"median":23.613932,"eighty":25.8411,"marketCap":4909382843}],"updateTime":1765588938149},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ECG\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1140449839","title":"Stock Track | Everus Construction Group Soars 13.14% on Impressive Q3 Results: Revenue Up 30%, EBITDA Rises 37%","url":"https://stock-news.laohu8.com/highlight/detail?id=1140449839","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140449839?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:12","pubTimestamp":1762355550,"startTime":"0","endTime":"0","summary":"Shares of Everus Construction Group, Inc. (ECG) are skyrocketing in Wednesday's pre-market trading, surging 13.14% following the release of impressive third-quarter financial results for 2025. The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ECG"],"gpt_icon":0},{"id":"1166162390","title":"Stock Track | Everus Construction Group Soars 10.82% Pre-market on Strong Q3 Results: 30% Revenue Growth, 37% EBITDA Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=1166162390","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166162390?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:53","pubTimestamp":1762350786,"startTime":"0","endTime":"0","summary":"Shares of Everus Construction Group, Inc. (ECG) are skyrocketing in pre-market trading on Wednesday, surging 10.82% following the release of impressive third-quarter financial results for 2025. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ECG"],"gpt_icon":0},{"id":"1165032560","title":"Stock Track | Everus Construction Group Soars 10.82% Pre-market on Strong Q3 Results: Revenue Up 30%, EBITDA Rises 37%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165032560","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165032560?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:53","pubTimestamp":1762350783,"startTime":"0","endTime":"0","summary":"Shares of Everus Construction Group, Inc. (ECG) surged 10.82% in pre-market trading on Wednesday, following the release of its impressive third-quarter 2025 financial results. The company reported...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ECG"],"gpt_icon":0},{"id":"2581773752","title":"Wearable Devices and X-trodes Successfully Deliver Neural Interface System for Dynamic, Real-World Environments","url":"https://stock-news.laohu8.com/highlight/detail?id=2581773752","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581773752?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:45","pubTimestamp":1762350300,"startTime":"0","endTime":"0","summary":"Yokneam Illit, Israel, Nov.  05, 2025  (GLOBE NEWSWIRE) -- Wearable Devices Ltd.(Nasdaq: WLDS, WLDSW) (the “Company” or “Wearable Devices”), a technology growth company specializing in artificial inte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181504/0/en/Wearable-Devices-and-X-trodes-Successfully-Deliver-Neural-Interface-System-for-Dynamic-Real-World-Environments.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1201861249.SGD","EOG","BK4129","LU2237438978.USD","LU0456854461.SGD","BK4588","LU0787776722.HKD","LU0070302665.USD","LU0788109394.HKD","TILE","ECG","IE00B3CCJ963.GBP","LU0208291251.USD","LU0053666078.USD","IE00B2Q91V27.USD","LU0266512473.USD","LU0256331488.USD","LU0368265418.SGD","BK4566","LU0300736492.USD","LU1074936037.SGD","IE00BGHQF524.EUR","LU0130102774.USD","LU0477156953.USD","LU0122376428.USD","BK4213","LU0648001328.SGD","LU0980610538.SGD","LU0320765489.SGD","LU0266512127.USD","LU0130517989.USD","BK4585","BK4143","LU0683600562.USD","LU0300736062.USD"],"gpt_icon":0},{"id":"2581720008","title":"Everus Construction Group Inc. reports 30% revenue growth and 37% EBITDA increase in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581720008","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581720008?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:21","pubTimestamp":1762348881,"startTime":"0","endTime":"0","summary":"Everus Construction Group Inc. reported a 30.0% increase in revenue for the third quarter of 2025, driven by continued momentum in the E&M segment, particularly in the data center submarket. EBITDA rose by 37.0% year-over-year, with the EBITDA margin improving to 9.0%, up 0.5 percentage points from the prior year. Free cash flow was $74.8 million, compared to $57.8 million in the prior period. Net cash provided by operating activities was $108.6 million, while capital expenditures totaled $42.1 million. The company's backlog reached $2.95 billion, reflecting a 2.0% increase from the previous year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everus Construction Group Inc. published the original content used to generate this news brie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL1nRjwW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4129","ECG"],"gpt_icon":0},{"id":"2581395798","title":"GUIDANCE: (ECG) Everus Expects Full Year 2025 Revenue Range $3.55B - $3.65B, vs. FactSet Est of $3.38B","url":"https://stock-news.laohu8.com/highlight/detail?id=2581395798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581395798?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:04","pubTimestamp":1762293844,"startTime":"0","endTime":"0","summary":"GUIDANCE: (ECG) Everus Expects Full Year 2025 Revenue Range $3.55B - $3.65B, vs. FactSet Est of $3.38B","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ECG.AU","ECG"],"gpt_icon":0},{"id":"2581760454","title":"Earnings Flash (ECG) Everus Posts Q3 EPS $1.11, vs. FactSet Est of $0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2581760454","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581760454?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:02","pubTimestamp":1762293766,"startTime":"0","endTime":"0","summary":"Earnings Flash (ECG) Everus Posts Q3 EPS $1.11, vs. FactSet Est of $0.62","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ECG","ECG.AU"],"gpt_icon":0},{"id":"2581762958","title":"Everus Construction Group Q3 EPS $1.11 Beats $0.65 Estimate, Sales $986.800M Beat $830.600M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581762958","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581762958?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:32","pubTimestamp":1762291935,"startTime":"0","endTime":"0","summary":"Everus Construction Group Q3 EPS $1.11 Beats $0.65 Estimate, Sales $986.800M Beat $830.600M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48638463/everus-construction-group-q3-eps-1-11-beats-0-65-estimate-sales-986-800m-beat-830-600m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Everus Construction Group Q3 EPS $1.11 Beats $0.65 Estimate, Sales $986.800M Beat $830.600M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4129","ECG"],"gpt_icon":0},{"id":"2581762979","title":"Everus Construction Group Inc. reports third quarter revenue of $986.8 million and net income of $57.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581762979","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581762979?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:31","pubTimestamp":1762291862,"startTime":"0","endTime":"0","summary":"Everus Construction Group Inc. reported third quarter 2025 revenues of $986.8 million, an increase of 29.7% compared to the same period last year. Net income rose 36.4% to $57.0 million, with a net income margin of 5.8%. Diluted earnings per share reached $1.11, up 35.4%. EBITDA was $89.0 million, marking a 36.9% increase, with an EBITDA margin of 9.0%. The company's backlog stood at $2.95 billion, up 6.0% from December 31, 2024, and 2.1% higher than September 30, 2024. Everus raised its full-year 2025 guidance, now expecting revenues between $3.55 billion and $3.65 billion and EBITDA between $290 million and $300 million. The E&M segment reported a 43% revenue increase and a 64% rise in EBITDA, supported by continued strength in the data center submarket. Gross capital expenditures for 2025 are projected to be between $65 million and $70 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL3XKQKq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4129","ECG"],"gpt_icon":0},{"id":"2581952762","title":"Everus Construction Group - Qtrly REV $986.8 Mln, Diluted EPS $1.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2581952762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581952762?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:30","pubTimestamp":1762291801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUAC9NS9G:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4129","ECG"],"gpt_icon":0},{"id":"2581762999","title":"Everus Construction Group Inc:  FY Revenues Expected to Be in Range of $3.55 Bln to $3.65 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581762999","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581762999?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:30","pubTimestamp":1762291801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUAC9NS9G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ECG","BK4129"],"gpt_icon":0},{"id":"2581624707","title":"Press Release: Everus Reports Third Quarter Results, Raises Guidance for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2581624707","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581624707?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:30","pubTimestamp":1762291800,"startTime":"0","endTime":"0","summary":"Everus Construction Group  today reported financial results for third quarter 2025.-- Earnings before interest, taxes, depreciation and amortization . of $89.0 million*, up 36.9%; EBITDA margin of 9.0%.\"We maintained strong business momentum through the third quarter, delivering record revenue and EBITDA driven by excellent project execution and robust opportunities across our core end markets,\" said Jeffrey S. Thiede, president and CEO of Everus. \"Revenues increased 30%, with margin expansion in both our E&M and T&D segments, resulting in 37% EBITDA growth. Our E&M segment increased revenue by 43% and EBITDA by 64%, supported by continued strength in the data center submarket.\"Thanks to the continued hard work and determination of our team members across the country who are safely Building America's Future, and with our elevated backlog and sustained business momentum, we expect a strong close to the year. We are raising our 2025 guidance and now expect revenues in the range of $3.55 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4129","ECG"],"gpt_icon":0},{"id":"2580494201","title":"CardioComm Secures $512,000 Loan to Advance ECG Software Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2580494201","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580494201?lang=en_us&edition=fundamental","pubTime":"2025-11-04 14:34","pubTimestamp":1762238077,"startTime":"0","endTime":"0","summary":"The latest update is out from Cardiocomm Solutions ( ($TSE:EKG) ). CardioComm Solutions has terminated a previously announced royalty agreement and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cardiocomm-secures-512000-loan-to-advance-ecg-software-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cardiocomm-secures-512000-loan-to-advance-ecg-software-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ECG","BK4129"],"gpt_icon":0},{"id":"2580136219","title":"Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580136219","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580136219?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:08","pubTimestamp":1762178880,"startTime":"0","endTime":"0","summary":"– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compell","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179404/0/en/Syndax-Announces-Compelling-Revuforj-revumenib-and-Niktimvo-axatilimab-csfr-Data-Accepted-for-Presentation-at-ASH-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2463526074.USD","BK4500","BK4139","BK4107","ALT","GGT","BK4020","BK4129","LU1878469433.USD","BK4197","LU1699723380.USD","BK4588","BK4008","BK4109","ALL","LU1571399168.USD","LU2355687059.USD","LU0985320562.USD","GILT","ASH","BK4533","CPK","HSCT","SAVE","BK4599","ECG"],"gpt_icon":0},{"id":"2580213983","title":"Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580213983","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580213983?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:00","pubTimestamp":1762174800,"startTime":"0","endTime":"0","summary":"Data show consistent efficacy, safety, and tolerability findings across multiple clinical trials that evaluated self-administered etripamilMONTREAL and CHARLOTTE, N.C., Nov.  03, 2025  (GLOBE NEWSWIRE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179176/0/en/Milestone-Pharmaceuticals-to-Present-New-Analysis-from-Investigational-Etripamil-Nasal-Spray-Clinical-Trials-for-PSVT-at-the-American-Heart-Association-Scientific-Sessions-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","ECG","BK4197","BK4107","BK4117","BK4129","SR"],"gpt_icon":0},{"id":"2579059911","title":"A Look at Everus Construction Group’s Valuation After Strong Q2 2025 Earnings Beat and Upgraded Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2579059911","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579059911?lang=en_us&edition=fundamental","pubTime":"2025-10-31 02:27","pubTimestamp":1761848833,"startTime":"0","endTime":"0","summary":"Everus Construction Group (ECG) surged to a new all-time high after its second-quarter 2025 results landed well above Wall Street’s forecasts. The company’s revenue jumped 31% from a year ago, and earnings per share exceeded consensus estimates.\nSee our latest analysis for Everus Construction Group.\nAfter surging on the back of stellar earnings, Everus Construction Group’s share price momentum has been impressive, with a 1-day gain of 1.09% and a 7-day share price return of 12.08%. This...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3041000-choice1-main-header/1585186744280"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-ecg/everus-construction-group/news/a-look-at-everus-construction-groups-valuation-after-strong","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-ecg/everus-construction-group/news/a-look-at-everus-construction-groups-valuation-after-strong","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","ECG","BK7064","ECG.AU","BK4129"],"gpt_icon":0},{"id":"2579496077","title":"New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $133B Cardiac Diagnostics Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2579496077","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579496077?lang=en_us&edition=fundamental","pubTime":"2025-10-29 01:50","pubTimestamp":1761673800,"startTime":"0","endTime":"0","summary":"Designed for investors, board members, and CEOs, the latest PatentVest Pulse report offers a strategic view of who’s leading and why in the rapidly evolving cardiac diagnostics marketDallas, TX, Oct. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/28/3175831/0/en/New-PatentVest-Pulse-Report-Maps-the-Competitive-and-IP-Landscape-of-the-133B-Cardiac-Diagnostics-Market.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1481599808.USD","IE00B3T34201.USD","BK4136","LU1169590202.USD","LU1481600234.SGD","BK4129","BK4585","ECG","LU1169589451.USD","LU2463526074.USD","LU1487256676.USD","IP"],"gpt_icon":0},{"id":"2579640349","title":"HeartBeam (NASDAQ: BEAT) Partners with HeartNexus to Deliver 24/7 Remote Cardiology Services and Real-Time ECG Interpretation","url":"https://stock-news.laohu8.com/highlight/detail?id=2579640349","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579640349?lang=en_us&edition=fundamental","pubTime":"2025-10-29 00:30","pubTimestamp":1761669008,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, October 28th, 2025, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardia...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/heartbeam-nasdaq-beat-partners-with-heartnexus-to-deliver-24-7-remote-cardiology-services-and-real-time-ecg-interpretation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/heartbeam-nasdaq-beat-partners-with-heartnexus-to-deliver-24-7-remote-cardiology-services-and-real-time-ecg-interpretation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","TSYW.SI","BEAT",".IXIC","BK4129","MNQmain","PSQ","USAW.SI","QID","ECG","NQmain","NVIW.SI","QLD","SQQQ","USJW.SI","TQQQ"],"gpt_icon":0},{"id":"2578430956","title":"zSpace Expands Health Science Portfolio with New Immersive Applications for Anatomy and ECG Training","url":"https://stock-news.laohu8.com/highlight/detail?id=2578430956","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578430956?lang=en_us&edition=fundamental","pubTime":"2025-10-28 19:45","pubTimestamp":1761651900,"startTime":"0","endTime":"0","summary":"Company to Showcase Solutions at NCHSE Conference and Spotlight Session on October 30SAN JOSE, Calif., Oct.  28, 2025  (GLOBE NEWSWIRE) -- zSpace, Inc. (NASDAQ: ZSPC), a global leader in immersive aug","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/28/3175298/0/en/zSpace-Expands-Health-Science-Portfolio-with-New-Immersive-Applications-for-Anatomy-and-ECG-Training.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","IE0009356076.USD","LU1852331112.SGD","IE00BQXX3C00.GBP","LU0107464264.USD","LU1974910355.USD","LU1917777945.USD","IE00BQXX3F31.USD","LU2417539215.USD","LU1623119135.USD","LU2023250330.USD","IE00BN29S564.USD","LU0964807845.USD","LU2213496289.HKD","LU0868494617.USD","LU0417517546.SGD","IE0004445239.USD","IE00BFSS8Q28.SGD","LU2108987350.USD","LU2361045086.USD","IE00B775H168.HKD","IE0004445015.USD","ZSPC","LU1712237335.SGD","IE00BQXX3D17.EUR","BK4533","LU2361044949.HKD","LU0353189680.USD","IE00BJJMRX11.SGD","CNA","LU2756315318.SGD","LU0127658192.USD","ECG","BK4534","LU0276348264.USD","LU1670628061.USD","LU1803068979.SGD","PCT","LU2462157665.USD","AR","LU0077335932.USD","LU1989772840.SGD","IE0004091025.USD","LU2361044865.SGD","LU1989772923.USD","LU0061474705.USD","LU2063271972.USD","MA","LU0971096721.USD","BK4213"],"gpt_icon":0},{"id":"2578544863","title":"Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2578544863","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578544863?lang=en_us&edition=fundamental","pubTime":"2025-10-25 01:58","pubTimestamp":1761328680,"startTime":"0","endTime":"0","summary":"– First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation – – Second approved indication for Revuforj in le","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/24/3173014/0/en/Syndax-Announces-FDA-Approval-of-Revuforj-revumenib-in-Adult-and-Pediatric-Patients-with-Relapsed-or-Refractory-NPM1-Mutated-Acute-Myeloid-Leukemia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0985320562.USD","BK4533","BK4561","CR","ALL","LU1699723380.USD","BK4144","LU1571399168.USD","BK4588","BK4581","ECG","ET","LU2355687059.USD","BK4107","BK4585","BK4590","BK4129","BK4161"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":73,"code":"91000000","status":"200"}]}}